Approval · Notice of Compliance 19793 · 2017
LENVIMA: Notice of Compliance 19793
Issued September 13, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19793
- Date
- September 13, 2017
- Company
- Eisai LimitedWoodcliff Lake, New Jersey, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma
Products in this notice
Medicinal ingredients
- LENVATINIB MESYLATE 8 MG per CAP
- LENVATINIB MESYLATE 18 MG per CAP